Session: Undergraduate Research Posters: Medicinal Chemistry:

Each year vancomycin resistant Staphylococcus aureus (VRSA) infects 1 million people and kills 11,500. VRSA has caused a growing health concern because the first case was reported in the United States in 2002. Vancomycin was initially used as a last resort treatment for methicillin resistant Staphylococcus aureus (MRSA). As a result, VRSA strains are often resistant to multiple drug classes including beta-lactams and glycopeptide antibiotics. Antibiotic adjuvants may be a promising new approach to combat antibiotic resistance because they potentiate our existing antibiotic arsenal. We screened a library of compounds for the ability to potentiate vancomycin in both VRSA and VISA strains. Novel scaffolds were identified from the active structures and a preliminary structure-activity relationship (SAR) was produced. Biological data, SAR, and initial mechanism of action studies will be presented.

Amaiya Anthony

Appearances